Fusion Pharmaceuticals

37 articles with Fusion Pharmaceuticals

• Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434

  6/14/2021

  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preliminary Phase 1 data from the single-dose portion of the study at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Virtual Annual Meeting

• Fusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. as Senior Vice President, Research

  6/7/2021

  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), today announced the appointment of Isabelle Dussault, Ph.D. as senior vice president, research.

• Fusion Pharmaceuticals Enters into Agreement to Build Radiopharmaceutical Manufacturing Facility

  6/2/2021

   Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it entered a 15-year lease agreement with Hamilton, Ontario-based McMaster University to build a 27,000 square foot current Good Manufacturing Practice (GMP

• Fusion Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

  5/27/2021

   Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 11:00am EDT.

• Fusion Pharmaceuticals Announces First Quarter 2021 Financial Results and Business Update

  5/11/2021

  Phase 1 study of FPI-1434 Phase 1 enrollment continues on track for data in 1H2022 Continuing expansion of pipeline of targeted alpha therapies through recently completed transactions

• Fusion Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate Fusion's Targeted Alpha Therapy (TAT) in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients With Solid Tumors Expressing IGF-1R

  5/6/2021

  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into a clinical trial collaboration with a subsidiary of Merck (known as MSD outside the U.S. and Canada)

• Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference

  4/14/2021

  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 10:30am EDT.

• Fusion Pharmaceuticals Announces Preclinical Combination Data Demonstrating Enhanced Efficacy in Multiple Preclinical Tumor Models

  4/10/2021

  Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced the presentation of preclinical data at the 2021 American Association for Cancer Research Virtual Annual Meeting.

• Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen

  4/1/2021

  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it has completed the acquisition of Ipsen's

• Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors

  4/1/2021

   Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines today announced the appointment of Donald A. Bergstrom, M.D., Ph.D., as a member of the Company's Board of Directors.

• Fusion Pharmaceuticals Announces Fourth Quarter 2020 Financial Results and Business Update

  3/25/2021

   Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), today announced financial results for the fourth quarter ended December 31, 2020 and provided an update on clinical and corporate developments.

• Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen

  3/2/2021

  Fusion to Leverage its Targeted Alpha Therapies (TAT) Expertise to Create FPI-2059, an Alpha-Emitting Radiopharmaceutical Targeting Solid Tumors

• Fusion Pharmaceuticals To Present At The Cowen 41st Annual Health Care Conference

  2/23/2021

  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in the "Novel Oncology Targets" panel discussion at the Cowen 41st Annual Health Care Conference

• Fusion Pharmaceuticals Appoints Philina Lee, Ph.D., to Board of Directors

  2/11/2021

  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Philina Lee, Ph.D., as a member of the Company's Board of Directors.

• Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors

  12/10/2020

  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the first patient has been dosed in the multi-dose portion of the Phase 1 study evaluating [225Ac]-FPI-1434 (FPI-1434) in patients with advanced solid tumors.

• Fusion Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

  11/12/2020

   Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a "fireside chat" presentation at the Jefferies Virtual London Healthcare Conference on Thursda

• Fusion Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update

  11/10/2020

  - Multi-dosing portion of Fusion's Phase 1 study of FPI-1434 on track to be initiated in Q4 2020 - Company executes collaboration agreement with AstraZeneca to grow pipeline of next-generation radiopharmaceuticals

• Fusion Pharmaceuticals Appoints Barbara Duncan as Chairperson of the Board of Directors

  11/2/2020

  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Barbara Duncan,

• Fusion Pharmaceuticals Announces Collaboration with AstraZeneca to Develop and Commercialize Next-Generation Radiopharmaceuticals and Combination Therapies

  11/2/2020

  Collaboration Combines Fusion's Targeted Alpha Therapies (TATs) Platform with AstraZeneca's Antibody and Oncology Portfolio to Create Novel Cancer Therapies

• Fusion Pharmaceuticals Appoints Maria Stahl as Chief Legal Officer

  9/29/2020

   Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Maria Stahl as chief legal officer.